Immunology of hepatitis B infection

Lancet Infectious Diseases

Volumn 2, Issue 1, 2002, Pages 43-50

  Jung, Maria Christina ^b   Pape, Gerd R ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; VIRUS ANTIGEN;

ANTIGEN PRESENTATION; CELL KILLING; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MONONUCLEAR CELL; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS INACTIVATION; VIRUS MUTATION;

EID: 0036461318     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00172-4     Document Type: Review

References (62)

1. Evans AA, London WT. Epidemiology of hepatitis B. In Zuckerman AJ, Thomas HC (editors.) Viral hepatitis. London: Harcourt, 1998: 107-14.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
3. Kazuhiro K, Guidotti LC, Yasuhiko K, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192: 921-30.
4. Delves PJ, Roitt IM. Advances in immunology: the immune system. N Engl J Med 2000; 343: 108-17.
5. Günther V, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52: 25-137.
6. Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T cell-independent and a T cell-dependent antigen. Science 1986; 234: 1398-401.
7. Maruyama T, Kuwata S, Koike K, et al. Precore wild-type DNA and immune complexes persist in chronic hepatitis B after seroconversion: no association between genome conversion and seroconversion. Hepatology 1998; 27: 245-53.
8. Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milch DR. The serology of chronic hepatitis B infection revisited. J Clin Invest 1993; 91: 2586-95.
9. Weimer T, Schödel F, Jung MC, et al. Antibodies to the RNase H domain of hepatitis B virus P protein are associated with ongoing viral replication. J Virol 1990; 64: 5665-68.
10. Stemler M, Weimer T, Tu Z-X, et al. Mapping of B-cell epitopes of the human hepatitis B virus X protein. J Virol 1990. 64: 2802-09.
11. Vitvitski-Trepo L, Kay A, Pichoud C, et al. Early and frequent detection of HBxAg and/or anti-HBx in hepatitis B virus infection. Hepatology 1990; 12: 1278-83.
12. Gerin JL. Experimental WHV infection of woodchucks: an animal model of hepadnavirus-induced liver cancer. Gastroenterol Jpn Suppl 1990;2:38-42
13. Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J, Mason WS. Woodchuck hepatitis virus infections:very rapid recovery after prolonged viremia and infection of virtually every hepatocyte. J Virol 1994; 68: 5792-803
14. Barker LF, Murray R. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. Am J Med Sci 1972; 263: 27-33.
15. Cote PJ, Korba BE, Miller RH, et al. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology 2000; 31: 190-200
16. Cote PJ, Toshkov I, Bellezza C, et al. Temporal pathogenesis of experimental neonatal woodchuck hepatitis virus infection; increased initial viral load and decreased severity of acute hepatitis during the development of chronic viral infection. Hepatology 2000; 32: 807-17
17. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60
18. Wirth S., Guidotti LG, Ando K, Schlicht HJ, Chisasri FV. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in HBV envelope transgenic mice. J Immunol 1995; 154: 2504-15.
19. Ando K, Guidotti LG, Wirth S, et al. Class I restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol 1994; 152: 3245-53.
20. Moriyama T, Guilhot S, Klopchin K, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990; 248: 361-64.
21. Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology: a transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178: 1541-54.
22. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 3764-68.
23. Franco A, Guidotti LG, Hobbs MV, Pasquetto V, Chisari FV. Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice. J Immunol 1997;159:2001-08.
24. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-29.
25. Jilbert AR, Botten JA, Miller DS, et al. Characterisation of age-and dose-related outcomes of duck hepatitis B virus infection. Virology 1998; 243: 273-82.
26. Hodgson PD, Michalak TI. Augmented hepatic interferon gamma expression and T cell influx characterize acute hepatitis progressing to recovery and residual lifelong virus persistence in experimental adult woodchuck hepatitis virus infection. Hepatology 2001; 34: 1049-59
27. Nakamura I, Nupp JT, Cowlen M, et al. Pathogenesis of experimental neonatal woodchuck hepatitis virus infection: chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology 2001; 33: 439-47.
28. Menne S, Maschke J, Klaes R, Roggendorf M. T cell response to woodchuck virus antigen during acute infection. In Rizzetto M, et al (eds). Viral hepatitis and liver disease. Turin: Edizioni minerva Medica, 1997; 453-57.
29. Tang N, Huang A, guo S, Qi Z, Zhang D. Comparison of specific immune responses to duck infected, immune, and uninfected ducks (Zhonghua Gan Zang Bing Za Zhi 2001; 9: 166-68.
30. Penna A, Bertoletti A, Cavalli A, et al. Fine specificity of the human T cell response to hepatitis B virus core antigen. Arch Virol 1992; 4: 23-28.
31. Webster GJM, Reignat S, Maini MK, et al. Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms. Hepatology 2000; 32: 1117-24.
32. Jung MC, Diepolder HM, Spengler U, et al. Activation of a heterogeneous hepatitis B(HB) core and e antigen-specific CD4+ T cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995; 69: 3358-68.
33. Penna A, Prete GD, Cavalli A, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997; 25: 1022-27.
34. Ferrari C, Penna A, Bertoletti A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 3442-9.
35. Jung M-C, Spengler U, Schraut W, et al. Hepatitis B virus antigen-specific T cell activation in patients with acute and chronic hepatitis B. J Hepatol 1991; 13: 310-17.
36. Tsai SL, Chen PJ, Lai MY, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis e antigen seroconversion. J Clin Invest 1992; 89: 87-96.
37. Beroletti A, D'Elios MM, Boni C, et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112: 193-9.
38. Penna A, Chisari FV, Bertoletti A, et al. Cytotoxic T lymphocytes recognize an HLA-A2 restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174: 1565-570.
39. Missale G, Redeker A, Person J, et al. HLA-A31 and Aw68 restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 1993; 177: 751-62.
40. Nayersina R, Fowler P, Guilhot S, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993: 150: 4659-71.
41. Maini M, Boni C, Ogg G, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+T cells associated with the control of infection. Gastroenterology 1999; 117: 1386-96.
42. Bertoletti A, Ferrari C, Fiaccadori F, et al. HLA class-I restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991; 88: 10445-449.
43. Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T cell response to multiple hepatitis - virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 1047-58.
44. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus perists for decades after patient's recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-08.
45. Bertoletti A, Costanzo A, Chisari F, et al. Cytotoxic T lymphocyte response to a wild-type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994; 180: 933-43
46. Chung MK, Yoon H, Min SS, et al. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in hepatitis B virus X antigen. J Immunother 1999; 22: 279-87.
47. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection, J Clin Invest 1996; 97: 1655-65
48. Ferrari C, Penna A, Giuberti T, et al. Intrahepatic nucleocapsid antigen-specific T cells in chronic active B. J Immunol 1987; 139: 2050-58.
49. Barnarba V, Franco A, Balsano A, Alberti C, Benvenuto R, Balsano F. Recognition of hepatitis B envelope proteins by liver- infiltrating T lymphocytes in chronic HBV infection. J Immunol 1989; 143: 2650-55.
50. Lohr H, Gerken G, Schlicht H, Meyer zum Büschenfelde KH, Fleischer B. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B. J Infect Dis 1993; 168: 1133-39.
51. Altman J, Moss P, Goulder D, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-96
52. Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8+ T Cells in liver damage and viral control during persistent hepatitis B virus infection, J Exp Med 2000; 191: 1269-80.
53. Stanford JL. The history and the future of vaccination immunotherapy for leprosy: Trop Geogr Med 1994; 46: 93-107
54. Strauss SE: The history and the future of vaccination with recombinant glycoprotein-D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994, 343: 1460-63
55. Pol S, Driss F, Carnot F, Michel ML, Berthelot P, Brechot C. Vaccination against hepatitis B virus: an efficient immunotherapy against hepatitis B multiplication. CR Acad SciIII 1993; 316: 688-91
56. Jung M-C, Grüner N, Zachoval R, et al. Therapeutic vaccination in chronic hepatitis B: Qualitative and quantitative analysis of the hepatitis B virusspecific immune response, submitted
57. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J Clin Invest 1995; 95: 341-49
58. Livingston BD, Crimi C, Grey H, Chesnut RW, Sette A. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. 1997; 159: 1383-92
59. Heathcote J, McHutchison J, Samuel L, et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 1999; 30: 531-6
60. Livingston BD, Alexander J, Crimi C, et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999; 162: 3088-95
61. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy: Hepatology 2001; 33: 963-971
62. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-75